Brian Droker, MD
Neurology · Carlsbad, CANPI 1801112669
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $247,635 of the $361,207 with a category attached, or 68.6%. It is spread thinly across 50 manufacturers, the largest accounting for just 23.8%. Among neurology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,130 payments — averaging $319.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$86K
- Teva Pharmaceuticals USA, Inc.$55K
- Amgen$53K
- Lundbeck LLC$51K
- Argenx US, Inc.$38K
- Lilly USA, LLC$18K
- plus $58K from 44 others
What the payments were for
- Consulting fees$65,40818%
- Speaking & faculty fees$247,63569%
- Grants$420%
- Travel & lodging$24,6327%
- Food & beverage$23,3446%
- Education$1460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$361,207 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UbrelvyUbrogepant | 35 | $34,437 |
| Nurtec OdtRimegepant Sulfate | 18 | $25,595 |
| BotoxOnabotulinumtoxina | 20 | $22,421 |
| Emgality PenGalcanezumab-Gnlm | 26 | $18,265 |
| Aimovig AutoinjectorErenumab-Aooe | 13 | $10,620 |
| Gabapentin | 94 | $1,348 |
| Duloxetine Hcl | 22 | $1,319 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 58 | $905 |
| Oxcarbazepine | 27 | $843 |
| Pyridostigmine Bromide | 14 | $506 |
| Propranolol Hcl ErPropranolol Hcl | 12 | $427 |
| Amitriptyline Hcl | 31 | $346 |
| Lamotrigine | 14 | $287 |
| Propranolol Hcl | 19 | $234 |
| Levetiracetam | 11 | $114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieUbrelvy, Botox | $86,037 | $56,85855 claims |
| PfizerNurtec Odt | $700 | $25,59518 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $72 | $50614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.
Other neurology in Carlsbad
- Andrew BlumenfeldCarlsbad$4.9M
- Jack SchimCarlsbad$1.7M
- Benjamin FrishbergCarlsbad$1.2M
- Bilal ChoudryCarlsbad$271K
- Khashayar DashtipourLoma Linda$3.3M
- Regina BerkovichWest Hollywood$3M
- Daniel BandariNewport Beach$2.6M
- Perry ShiehLos Angeles$2.4M
- Sandeep ThakkarIrvine$2M
- David LiebeskindLos Angeles$1.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.